A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM)

Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment

NCT01316224 ·Status: COMPLETED

Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00645892 ·Status: COMPLETED ·Phase: PHASE2

Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis

NCT01722214 ·Status: COMPLETED ·Phase: PHASE4

Safety and Efficacy of Adalimumab in Patients Who Showed an Unsatisfactory Response to Etanercept

NCT00927069 ·Status: COMPLETED ·Phase: PHASE3

Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy

NCT00566722 ·Status: COMPLETED ·Phase: PHASE3

Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00645814 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis

NCT01646073 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis

NCT01925768 ·Status: COMPLETED ·Phase: PHASE3

Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00646191 ·Status: COMPLETED ·Phase: PHASE2

Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet

NCT00735787 ·Status: COMPLETED ·Phase: PHASE4

Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00235820 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis

NCT00195689 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

NCT01172938 ·Status: COMPLETED ·Phase: PHASE3

Quality of Life in Adalimumab Treated Psoriasis Patients Failing Other Biologic Disease Modifying Anti-rheumatic Drugs

NCT01084668 ·Status: COMPLETED

Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis

NCT00456092 ·Status: COMPLETED ·Phase: PHASE2

Adalimumab in Adult Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00338754 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Greek Study of the Quality of Life in Patients With Psoriasis Treated With Adalimumab

NCT01077128 ·Status: COMPLETED

Mechanism of Action Study for Psoriasis

NCT00932113 ·Status: COMPLETED ·Phase: PHASE4

Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis

NCT04209205 ·Status: COMPLETED ·Phase: PHASE3

Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab.

NCT01320293 ·Status: COMPLETED ·Phase: NA

Adalimumab Biosimilar in Clinical Practice

NCT04808739 ·Status: COMPLETED

Effect of Adalimumab on Vascular Inflammation in Patients With Moderate to Severe Plaque Psoriasis

NCT00940862 ·Status: COMPLETED ·Phase: PHASE4

A Study of Ixekizumab in Participants With Active Psoriatic Arthritis

NCT01695239 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Adalimumab in Patients With Psoriasis and Obstructive Sleep Apnea

NCT01181570 ·Status: COMPLETED ·Phase: PHASE4

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

NCT03104400 ·Status: COMPLETED ·Phase: PHASE3